Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Diabetes Mellitus, Type 2
Interventions
Pioglitazone 15 mg, Pioglitazone 45 mg, Pioglitazone 30 mg, Linagliptin 5mg / Pioglitazone 45 mg FDC, Linagliptin 5mg / Pioglitazone 30 mg FDC, Linagliptin 5mg, Linagliptin 5mg / Pioglitazone 15 mg FDC
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
936 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
74
States / cities
Birmingham, Alabama • Montgomery, Alabama • Muscle Shoals, Alabama + 60 more
Completed Not applicable Interventional Results available

Effect of Adipokines in Hemodialysis Patients

NCT01301027
Conditions
End Stage Renal Disease
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Denver, Colorado • Salt Lake City, Utah
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function

NCT00845182
Conditions
Type 2 Diabetes, Healthy, Impaired Glucose Tolerance
Interventions
Pioglitazone, Exenatide, Pioglitazone and Exenatide
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Type1diabetes
Interventions
Dapagliflozin 10mg Tab, Pioglitazone 15 MG and 30mg, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Completed Phase 1Phase 2 Interventional Results available

PPARγ Agonist Treatment for Cocaine Dependence

NCT02774343
Conditions
Cocaine Use Disorder, Alcohol Use Disorder
Interventions
Pioglitazone, Placebo, Therapy, Contingency Management
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Conditions
Type 2 Diabetes (Adult Onset)
Interventions
Tirzepatide, Pioglitazone, Sitagliptin, Metformin HCI XR
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 75 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
San Antonio, Texas